Jasper Therapeutics (JSPRW) Stock Price, News & Analysis

Company Overview

Jasper Therapeutics, Inc. is a clinical‐stage biopharmaceutical company focused on developing a new generation of cellular therapeutics for severe diseases. The company’s mission centers on harnessing targeted biological agents and engineered cell platforms to improve outcomes in hematopoietic stem cell transplantation, oncology and gene therapies. By advancing novel approaches to conditioning regimens and cell engineering, Jasper aims to address limitations of existing treatments, including toxicity, graft failure and restricted applicability.

The company’s lead candidate, JSP191, is a humanized monoclonal antibody targeting the CD117 receptor on hematopoietic stem cells. JSP191 is designed to enable safer, more precise conditioning prior to stem cell transplantation and in vivo gene therapy by selectively depleting endogenous stem cells while sparing other bone marrow elements. Jasper is also exploring additional cell engineering programs that leverage proprietary platforms to develop next-generation cell therapies, including targeted immunotherapies and regenerative medicine applications.

Headquartered in Boston, Massachusetts, Jasper Therapeutics conducts research and development activities in North America and collaborates with academic institutions and industry partners to advance its pipeline. The company’s leadership team brings experience in biologics development, clinical operations and cell therapy manufacturing, positioning Jasper to navigate the regulatory landscape and scale its technologies for broader patient access. Through strategic alliances and a focus on translational science, Jasper aims to move its most promising candidates toward pivotal clinical milestones.

Key Stats

• Today's Range: $0.11 to $0.11
• 50-Day Range: $0.05 to $0.11
• 52-Week Range: $0.04 to $0.25
• Volume: 462 shs
• Average Volume: 8,270 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

JSPRW Stock Analysis - Frequently Asked Questions

How have JSPRW shares performed this year?

Jasper Therapeutics' stock was trading at $0.2096 at the start of the year. Since then, JSPRW shares have decreased by 51.8% and is now trading at $0.1010.

How do I buy shares of Jasper Therapeutics?

Shares of JSPRW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:JSPRW
• CIK: 1788028
• Web: N/A
• Phone: 650-549-1400
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A